We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDER Outlines Its Regulatory Approach to Nanomaterials in Drug Products
CDER Outlines Its Regulatory Approach to Nanomaterials in Drug Products
The FDA’s Center for Drug Evaluation and Research (CDER) released a final guidance yesterday on drugs and biologics that contain nanomaterials, noting that the agency has not yet established regulatory definitions of nanomaterials and nanotechnology.